Skip to main content

Press Release

Press Release: National Boards of Pharmacy Conference Focuses on Medical Marijuana

FOR IMMEDIATE RELEASE: December 3, 2009 CONTACT: ASA Media Liaison Kris Hermes at 510-681-6361 National Boards of Pharmacy Conference Focuses on Medical Marijuana Advocacy Group Presents on Medical Marijuana Alongside AMA & Other Health Experts Tucson, AZ -- As pharmacists and drug regulators from across the country convene in Tucson this week for their Winter symposium, they will be discussing medical marijuana, an issue which is headlining the agenda. The National Association of Boards of Pharmacy (NABP) opens its symposium on Thursday with several presentations on medical marijuana by an array of speakers and experts, including Caren Woodson, Government Affairs Director with Americans for Safe Access, the country's largest advocacy organization focused on the issue. "We welcome the interest in medical marijuana by the Boards of Pharmacy and want to work with them to address this public health issue," said Woodson. "State Boards of Pharmacy can have an impact on medical marijuana and we want to work with them to adopt sensible policies." The Oregon Board of Pharmacy has been ordered to remove marijuana from its state list of Schedule I drugs, per legislation signed by Governor Kulongoski in August. In addition, the Iowa Board of Pharmacy is currently considering rescheduling marijuana as a result of litigation. Woodson will co-present on a panel Thursday morning with Barry D. Dickinson, the Director of Science & Biotechnology for the American Medical Association, and Alice Mead, the Director of U.S. Public Relations for GW Pharmaceuticals, a U.K. company conducting clinical trials for a medical marijuana extract. The panel is entitled, "Should Marijuana be a Medical Option?" Later, Woodson will take part in a point-counterpoint on medical marijuana with Dickinson, Mead and other experts, including Andrea Barthwell, former deputy director for the U.S. Office of National Drug Control Policy and other marijuana researchers. The NABP symposium will be attended by Boards of Pharmacy executive officers, members, and other state and federal regulators as well as stakeholders in the pharmaceutical industry. Both the California Attorney General's office and the California Department of Public Health are sending representatives to the symposium. Attendees will be able to earn continuing pharmacy education credit for their participation in medical marijuana panels. The mission of the NABP is to assist its member boards in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health. The State Boards of Pharmacy oversee the classification of controlled substances, such as marijuana, at the state level, similar to the way that the Food & Drug Administration (FDA) and the Drug Enforcement Administration (DEA) oversee the federal classification of controlled substances. While state controlled substance lists routinely match the federal list, the State Boards of Pharmacy can change the classification of particular drugs independent of the federal government. The NABP symposium follows a report on medical marijuana issued last month by the American Medical Association, in which the oldest and largest physician-based group in the U.S. urged the federal government to review the Schedule I status for marijuana. The AMA noted that marijuana appeared to be efficacious for several health conditions and said that further research was needed to assess whether marijuana should continue to be considered a dangerous drug with no medical value. Further Information: The National Association of Boards of Pharmacy 2009 Symposium Schedule: http://www.nabp.net/whatsnew/meetings/2009symposium/ ASA National Policy Platform: http://www.safeaccessnow.org/downloads/ASA_Natl_Policy_Agenda_09-11.pdf # # #

Landmark Medical Marijuana Hearings Tomorrow in Harrisburg

FOR IMMEDIATE RELEASE

Pennsylvanians for Medical Marijuana

www.pa4mmj.org 

WHO: Pennsylvania House Health and Human Services committee

WHAT: Public Hearings on HB 1393, medical marijuana in PA

WHEN: December 2, 2009 Room 140 at 11AM, Main Capitol in Harrisburg

CONTACT: Chris Goldstein cellphone 505 577 5093 or email [email protected]

**UPDATE**

A Press Conference with Rep. Cohen and PA4MMJ patients will take place at 10:00AM at the East Rotunda

 

Landmark Medical Marijuana Hearings Tomorrow in Harrisburg

December 1, 2009

Philadelphia- Advocates and patients with the group Pennsylvanians for Medical Marijuana (PA4MMJ) will testify tomorrow before the PA House of Representatives Health and Human Services Committee during hearings on HB 1393, The Compassionate Use Medical Marijuana Act.

 

These will be the first public hearings on medical cannabis in the history of the Commonwealth.

On April 29, 2009 Rep. Mark B. Cohen introduced the bill to legalize medical marijuana with PA4MMJ. HB1393 would allow registered patients to grow six plants or purchase cannabis through Compassion Centers. A provision in the bill allows these medical cannabis sales to be taxed.

At a press conference at the bill’s introduction Cohen said, "It's time to create a new, honest image for marijuana. One as a form of treatment that when prescribed by responsible doctors could help thousands of patients across this commonwealth."

Three newspaper Editorial Boards endorsed the bill immediately after it was introduced: The Philadelphia Inquirer, The Pocono Record and the Daily Review of Towanda.

 

Testifying in favor of the bill: Chris Goldstein and Derek Rosenzweig of PA4MMJ; Ed Pane of Serento Gardens Treatment Center; Bradley Walter who lives with HIV; Andrew Hoover of the ACLU-PA, Criminal Defense Attorney Patrick Nightengale; MS patient John Wilson of New Jersey; Brian Gralnick of JSPAN; Bob Ceppecio of The Marijuana Policy Project along with other local patients and professionals. Signed written testimony from 26 PA residents will be presented by PA4MMJ along with 19 written submissions sent anonymously. Expert written submissions and comments came from the AIDS Law Project of Pennsylvania, the National Lawyers Guild Philadelphia Chapter, The Coalition for Medical Marijuana New Jersey and the National Organization for the reform of Marijuana Laws Deputy Director Paul Armentano.

Several groups will testify in opposition to medical cannabis including the PA Elks Association.

The December 2nd hearings are informational and will not see a vote. The twenty-six-member committee may ask questions of the presenters and PA4MMJ is expecting a lively and educational discussion. Please visit www.pa4mmj.org

MEDIA MAY CONTACT CHRIS GOLDSTEIN DIRECTLY [email protected]

Press Release: California Budget Deficit Balloons, While Prisons on Schedule to Overspend by $1.4 Billion

FOR IMMEDIATE RELEASE: November 18, 2009 CONTACT: Margaret Dooley-Sammuli at (213) 291-4190 or Stephen Gutwillig at (323) 542-6510 California Budget Deficit Balloons, While Prisons on Schedule to Overspend by $1.4 Billion Advocates Condemn Sacramento’s Priorities: “California’s Incarceration Spending Locks Up Our Tax Dollars” SACRAMENTO – The nonpartisan Legislative Analyst’s Office announced today that it expects the California state budget deficit to exceed $20 billion by the end of the 2010-11 fiscal year, and that the state will spend $1.4 billion more on prisons than was budgeted in 2009-10. Advocates criticize the state for failing to make real cuts to prison spending, while enacting brutal cuts to important social services. “California’s prison spending is totally out of whack and it’s locking up tax dollars that now aren’t available for education and other community services like fire protection and elder care,” said Margaret Dooley-Sammuli, deputy state director for the Drug Policy Alliance in Southern California. “Other states, like New York, have reduced their crime rates and their prison populations at the same time. California should follow their lead.” The Legislature and governor approved $1.2 billion in unallocated cuts to the California Department of Corrections and Rehabilitation (CDCR) in late July. On September 11, the Legislature sent a bill to the governor that would realize just $200-300 million in cuts. According to the LAO’s report, prison spending will exceed its 2009-10 budgeted level by $1.4 billion. “Sacramento said that it would cut prison spending by $1.2 billion – but that was a lie. That should come as no surprise; the prisons have overspent their budget by hundreds of millions of dollars in each of the past several years,” Dooley-Sammuli continued. “With the state near fiscal collapse, this just won’t do any longer. Prisons, like other resources, should be used wisely. They simply aren’t the right place for people convicted of petty offenses, particularly low-level, non-violent drug law violations.” According to the CDCR, over 30,000 people are locked up in California state prisons for a non-violent drug offense – at a total cost of $1.5 billion per year. Instead of reducing costs by addressing the number of people incarcerated for petty drug offenses, however, the state recently announced that it would cut by 70% the amount of drug treatment offered behind bars and by 40% the amount of drug treatment offered on parole. The LAO report is online at: http://www.lao.ca.gov/laoapp/PubDetails.aspx?id=2143 # # #

Press Release: NJ Senate Comm. to Vote on Reforming Mandatory Minimum Drug Laws

FOR IMMEDIATE RELEASE: November 18, 2009 CONTACT: Tony Newman at 646-335-5384 or Roseanne Scotti at 609-610-8243 NJ Senate Judiciary Committee to Vote Monday on Groundbreaking Sentencing Bill that Would Give Judges the Discretion to Waive Mandatory Minimum Sentences for Some Nonviolent Drug Offenses Advocates Commend Legislation as Common-Sense and Reasonable Reform that Would Increase Fair and Effective Sentencing and Save Taxpayer Money On Monday, November 23, the Senate Judiciary Committee will consider Senate Bill 1866, which would give judges the discretion to waive mandatory minimum sentences for some nonviolent drug offenses. The Assembly passed the companion legislation, A2762, last year and Gov. Jon Corzine has said he will sign the bill when it gets to his desk. This critically important legislation would be a groundbreaking first step in reforming New Jersey’s draconian sentencing laws for nonviolent drug offenses. Roseanne Scotti, director of Drug Policy Alliance New Jersey, applauded the committee’s willingness to consider the bill and urged passage. “Twenty years ago, New Jersey began implementing harsh mandatory minimum sentences for nonviolent drug offenses. These laws have been a spectacular failure. They have done nothing to decrease drug activity and have filled New Jersey’s prisons with nonviolent drug offenders at great cost to New Jersey taxpayers,” said Scotti. It costs New Jersey taxpayers more than $46,000 a year to incarcerate an individual and New Jersey spends about $331 million a year just to incarcerate nonviolent drug offenders. Allowing judges some discretion would guarantee that justice is done and that taxpayer dollars are not wasted. At a time when New Jersey is facing serious budget deficits and cutting spending on education, health and other critical programs, advocates say New Jersey needs to take a hard look at policies that have mandated the warehousing of large numbers of nonviolent drug offenders at enormous cost to taxpayers. S1866/A2762 is supported by a broad coalition of organizations including Volunteers of American Delaware Valley, Corporation for Supportive Housing, New Jersey Association on Correction, New Jersey Institute for Social Justice, Coalition of Community Corrections Providers of New Jersey, Women Who Never Give Up, Families Against Mandatory Minimums, Hispanic Directors Association and Latino Leadership Alliance. Recently, both the Newark and Camden City Councils passed resolutions supporting S1866. When New Jersey adopted the Comprehensive Drug Reform Act in 1986, the state ushered in a radical era of harsh mandatory minimum sentences for nonviolent drug offenses. This led to unprecedented levels of incarceration and massive taxpayer expenditures. These unfair and ineffective laws have also had an egregiously disproportionate impact on communities of color. • In 1987, only 11 percent of the New Jersey prison population was incarcerated for drug offenses. Today, 29 percent of the prison population is incarcerated for nonviolent drug offenses. • Twenty years ago, only 11 percent of individuals in prison were serving mandatory minimum sentences—today 69 percent are serving mandatory terms. • In the last twenty years, New Jersey’s Corrections budget has risen from $289 million to $1.3 billion. • New Jersey spends $331 million a year to incarcerate individuals for nonviolent drug offenses. • The budget for corrections has grown by a factor of 13 while the overall budget grew only by a factor of six. • In the 1980s and 1990s, the Corrections budget grew at three times the rate of the budget for education. • Although African Americans and Latinos account for just 27 percent of the population of New Jersey, they represent 81 percent of the prison population. # # #

Press Release: AMA Report Recognizes Medical Benefits of Marijuana, Urges Further Research

PRESS RELEASE Americans for Safe Access For Immediate Release: November 10, 2009 AMA Report Recognizes Medical Benefits of Marijuana, Urges Further Research Largest and oldest U.S. physician-based group reverses long-held position on medical marijuana Houston, TX -- The American Medical Association (AMA) voted today to reverse its long-held position that marijuana be retained as a Schedule I substance with no medical value. The AMA adopted a report drafted by the AMA Council on Science and Public Health (CSAPH) entitled, "Use of Cannabis for Medicinal Purposes," which affirmed the therapeutic benefits of marijuana and called for further research. The CSAPH report concluded that, "short term controlled trials indicate that smoked cannabis reduces neuropathic pain, improves appetite and caloric intake especially in patients with reduced muscle mass, and may relieve spasticity and pain in patients with multiple sclerosis." Furthermore, the report urges that "the Schedule I status of marijuana be reviewed with the goal of facilitating clinical research and development of cannabinoid-based medicines, and alternate delivery methods." The change of position by the largest physician-based group in the country was precipitated in part by a resolution adopted in June of 2008 by the Medical Student Section (MSS) of the AMA in support of the reclassification of marijuana's status as a Schedule I substance. In the past year, the AMA has considered three resolutions dealing with medical marijuana, which also helped to influence the report and its recommendations. The AMA vote on the report took place in Houston, Texas during the organization's annual Interim Meeting of the House of Delegates. The last AMA position, adopted 8 years ago, called for maintaining marijuana as a Schedule I substance, with no medical value. "It's been 72 years since the AMA has officially recognized that marijuana has both already-demonstrated and future-promising medical utility," said Sunil Aggarwal, Ph.D., the medical student who spearheaded both the passage of the June 2008 resolution by the MSS and one of the CSAPH report's designated expert reviewers. "The AMA has written an extensive, well-documented, evidence-based report that they are seeking to publish in a peer-reviewed journal that will help to educate the medical community about the scientific basis of botanical cannabis-based medicines." Aggarwal is also on the Medical & Scientific Advisory Board of Americans for Safe Access (ASA), the largest medical marijuana advocacy organization in the U.S. The AMA's about face on medical marijuana follows an announcement by the Obama Administration in October discouraging U.S. Attorneys from taking enforcement actions in medical marijuana states. In February 2008, a resolution was adopted by the American College of Physicians (ACP), the country's second largest physician group and the largest organization of doctors of internal medicine. The ACP resolution called for an "evidence-based review of marijuana's status as a Schedule I controlled substance to determine whether it should be reclassified to a different schedule. "The two largest physician groups in the U.S. have established medical marijuana as a health care issue that must be addressed," said ASA Government Affairs Director Caren Woodson. "Both organizations have underscored the need for change by placing patients above politics." Though the CSAPH report has not been officially released to the public, AMA documentation indicates that it: "(1) provides a brief historical perspective on the use of cannabis as medicine; (2) examines the current federal and state-based legal envelope relevant to the medical use of cannabis; (3) provides a brief overview of our current understanding of the pharmacology and physiology of the endocannabinoid system; (4) reviews clinical trials on the relative safety and efficacy of smoked cannabis and botanical-based products; and (5) places this information in perspective with respect to the current drug regulatory framework." Further information: Executive Summary of AMA Report: http://AmericansForSafeAccess.org/downloads/AMA_Report_Executive_Summary.pdf Recommendations of AMA Report: http://AmericansForSafeAccess.org/downloads/AMA_Report_Recommendations.pdf American College of Physicians resolution: http://www.acponline.org/advocacy/where_we_stand/other_issues/medmarijuana.p df # # # With over 30,000 active members in more than 40 states, Americans for Safe Access (ASA) is the largest national member-based organization of patients, medical professionals, scientists and concerned citizens promoting safe and legal access to cannabis for therapeutic use and research. ASA works to overcome political and legal barriers by creating policies that improve access to medical cannabis for patients and researchers through legislation, education, litigation, grassroots actions, advocacy and services for patients and the caregivers.

AMA Calls for Review of Medical Marijuana’s Legal Status

FOR IMMEDIATE RELEASE                                                                                           
NOVEMBER 10, 2009

AMA Calls for Review of Medical Marijuana’s Legal Status

New Policy Marks Historic Shift From Prior Stance

CONTACT: Bruce Mirken, MPP director of communications …………… 415-585-6404 or 202-215-4205

HOUSTON, TEXAS — In a move considered historic by supporters of medical marijuana, the American Medical Association’s House of Delegates today adopted a new policy position calling for the review of marijuana’s status as a Schedule I drug in the federal Controlled Substances Act. The old language in Policy H-95.952 had previously recommended that “marijuana be retained in Schedule I,” which groups marijuana with drugs such as heroin, LSD and PCP that are deemed to have no accepted medical uses and to be unsafe for use even under medical supervision.

         The revised policy, adopted today, states, “Our AMA urges that marijuana’s status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods.” It goes on to explain that this position should not be construed as an endorsement of state medical marijuana programs.

         “This shift, coming from what has historically been America’s most cautious and conservative major medical organization, is historic,” said Aaron Houston, director of government relations for the Marijuana Policy Project, who attended the AMA meeting. “Marijuana’s Schedule I status is not just scientifically untenable, given the wealth of recent data showing it to be both safe and effective for chronic pain and other conditions, but it’s been a major obstacle to needed research.”

         Drugs listed in Schedule II, for which medical use is permitted with strict controls, include cocaine, morphine and methamphetamine. A pill containing THC, the component responsible for marijuana’s “high,” is classed in Schedule III, whose looser requirements allow phoned-in prescriptions.

         With more than 29,000 members and 100,000 e-mail subscribers nationwide, the Marijuana Policy Project is the largest marijuana policy reform organization in the United States. MPP believes that the best way to minimize the harm associated with marijuana is to regulate marijuana in a manner similar to alcohol. For more information, please visit http://MarijuanaPolicy.org.

####

Press Release: Montel Williams to Receive Awards for Drug Policy Work

FOR IMMEDIATE RELEASE: November 5, 2009 CONTACT: Tony Newman at 646-335-5384 or Tommy McDonald at 636-335-2242 Montel Williams, Celebrated Talk Show Host and Medical Marijuana Patient/Advocate, to Receive Award at International Drug Policy Reform Conference in New Mexico Award Recognizes Williams' Pioneering Advocacy for Compassionate Drug Laws and Safe Access to Medical Marijuana Montel Williams, veteran TV talk show host and currently the host of Montel Across America, a nationally syndicated daily radio show, will receive the The Edward M. Brecher Award for Achievement in the Field of Journalism at the International Drug Policy Reform Conference in Albuquerque, New Mexico on Nov. 13, 2009. Williams, who suffers from multiple sclerosis and uses medical marijuana to relieve chronic nerve pain, is being honored by the Drug Policy Alliance for his groundbreaking journalism and outspoken advocacy on behalf of medical marijuana patients and providers. Williams will accept the award during the conference awards dinner, which begins at 7:30 p.m. at the Hyatt Regency Albuquerque. Since going public with his personal medical marijuana use in late 2003, Williams has tirelessly campaigned for changes in state and federal laws to expand access to marijuana as a medicine. In addition to writing Climbing Higher, his 2004 autobiography that detailed his struggle with MS and the therapeutic effects of cannabis, Williams has hosted TV shows on the topic of medical marijuana, authored Op-Ed pieces in major newspapers and used his platform as a public figure to press legislators across the country to enact new drug policies based on compassion, reason and science. In particular, Williams traveled to state capitals in Albany, NY and Trenton, NJ, as well as Washington, D.C., to urge elected officials to pass medical marijuana legislation. "I utilize medical marijuana to help alleviate the extreme neuralgic pain I suffer from," said Montel Williams. "I am not alone. There are thousands of patients like me, and we should not be treated as criminals." “Montel is in a league of his own insofar as the effort to legalize medical marijuana is concerned,” said Ethan Nadelmann, executive director of the Drug Policy Alliance. “No one has used his media pulpit as effectively and passionately as he has in combating drug war intransigence.” The Drug Policy Alliance, the nation's leading organization promoting policy alternatives to the drug war, bestows the biennial Edward M. Brecher Award to media figures who show the courage and leadership to question official drug war propaganda. Previous recipients include: ABC News Anchor Hugh Downs; Cartoonist Gary Trudeau; The Economist magazine; Rolling Stone magazine; William Finnegan, staff writer for The New Yorker; and Eric Schlosser, author of Fast Food Nation and Reefer Madness, among other distinguished honorees. The International Drug Policy Reform Conference, co-hosted by the Drug Policy Alliance in Albuquerque, NM from Nov. 12-14, 2009, brings together nearly 1000 leading international experts, treatment providers, researchers, policymakers and key activists at the leading global forum on drug policy reform. For more information or to register for the conference, please visit www.reformconference.org. To purchase tickets for the awards ceremony: http://www.regonline.com/Checkin.asp?EventId=784745.

Press Release: NY State Assemblyman Aubry to Receive Award for Drug Policy Work

FOR IMMEDIATE RELEASE: November 5, 2009 CONTACT: Tony Newman at 646-335-5384 NY State Assemblyman Jeffrion L. Aubry, Chief Sponsor of Historic Rockefeller Drug Law Reform Legislation, to Receive Award at International Drug Policy Reform Conference in New Mexico Award Recognizes Aubry's Leadership and Tenacity in Successful Effort to Roll Back Draconian New York State Drug Laws New York State Assemblyman Jeffrion L. Aubry, a longtime champion of efforts to reform New York's harsh Rockefeller Drug Laws, will receive the Justice Gerald Le Dain Award for Achievement in the Field of Law at the International Drug Policy Reform Conference in Albuquerque, New Mexico on Nov. 13, 2009. Aubry, who introduced bills to repeal New York's mandatory drug sentencing laws in every legislative session since 1997, is being honored by the Drug Policy Alliance for his unyielding commitment to reform culminating in this year's passage of sweeping changes to the Rockefeller laws. The Justice Gerald Le Dain Award for Achievement in the Field of La is bestowed on those involved in the law who work within official institutions to challenge traditional drug war orthodoxy. Previous recipients include: Congressman John Conyers, Jr. (D-MI); federal judges Robert Sweet (NY) and John Kane (Denver); former police chiefs Joseph D. McNamara ( Kansas City and San Jose) and Nicholas Pastore (New Haven, CT); Canadian Member of Parliament Libby Davies; and other distinguished attorneys, activists, judges and others. Aubry, chair of the Assembly Standing Committee on Correction, led the successful fight to repeal mandatory minimum sentences for most low-level, nonviolent drug offenses in New York and instead return discretion to judges to determine whether to divert individuals to treatment or probation instead of incarceration. The reforms, signed into law in April by New York Gov. David Paterson and enacted in October, signal a shift toward treating drug use as public health issue rather a criminal justice matter. "Thirty-five years of a drug policy focused on punishing drug users and spending billions of dollars on incarceration has failed to reduce drug use or drug-related crime," Aubry said. "Unfortunately, we have spent hundreds of millions of dollars locking up individuals, mostly African-Americans and Latinos, with drug abuse problems rather than offering them needed drug treatment. This historic reform enacts a sensible, comprehensive and cost-effective approach for dealing with nonviolent drug offenders and will ensure that drug abusers are able to access effective substance abuse treatment and counseling." Aubry has represented the 35th Assembly District in Queens since 1992. He previously served as Director of Economic Development for the Borough President's Office of Queens. For 16 years, he worked in the drug treatment program at Elmcor Youth and Adult Activities, one of the largest nonprofit social service agencies in Queens. Ethan Nadelmann, executive director of the Drug Policy Alliance, said, “I don’t know of any state legislator in the country who has fought so long, so hard, and now so successfully to reform a drug war injustice as Jeff Aubry.” The International Drug Policy Reform Conference, co-hosted by the Drug Policy Alliance in Albuquerque, NM from Nov. 12-14, 2009, is the outstanding gathering in the world of people working to reform local, national and foreign drug policies. For more information or to register for the conference, please visit www.reformconference.org. To purchase tickets for the awards ceremony: http://www.regonline.com/Checkin.asp?EventId=784745.

Press Release -- New Report: Marijuana Arrests Don't Affect Use; Penalty Structure Boosts Illegal Market

FOR IMMEDIATE RELEASE                                                                                             
NOVEMBER 5, 2009           

 

Most Exhaustive Set of Marijuana Arrest Data Ever Shows No Relation Between Arrests and Use Rates; Penalty Structure Boosts Illicit Market
Florida Has Toughest Penalties, Arrest Rate Highest in D.C, Black Arrest Rate 3 Times That of Whites

CONTACT: Bruce Mirken, MPP director of communications …………… 415-585-6404 or 202-215-4205

                  Jon Gettman ………………………………………………...……………………540-822-5739

WASHINGTON, D.C. — The most exhaustive collection of data ever on U.S. marijuana arrests, penalties and related information, released today, finds no relationship between marijuana arrest and use rates, while penalty structures act as a price support mechanism that boosts the illegal market. Assembled by Jon Gettman, Adjunct Assistant Professor in Criminal Justice at Shenandoah University in Winchester, Virginia, the new report finds:

·      Marijuana arrests have nearly doubled since 1991, while levels of marijuana use remained fundamentally unchanged.

·      Penalties that escalate for increased amounts of marijuana encourage consumers to make multiple small purchases, acting as a price support for the illicit market.

·      Florida has the nation’s harshest marijuana penalties, while the District of Columbia has the highest arrest rate for marijuana offenses.

·      Although the rate of marijuana use is only about 25 percent higher for African-Americans than for whites, blacks are three times as likely to be arrested for marijuana possession as whites.

         “These figures paint a devastating portrait of a failed policy that burns through tax dollars while doing nothing but harm,” said Rob Kampia, executive director of the Marijuana Policy Project in Washington, D.C. “Most Americans agree that marijuana prohibition doesn’t work, even if most politicians aren’t yet ready to publicly agree with their constituents.”

          Gettman’s summary report, “Marijuana Arrests in the United States (2007),” is available at http://www.drugscience.org/Archive/bcr7/bcr7_index.html. The full Marijuana Policy Almanac, including state rankings and individual reports for all 50 states plus the District of Columbia, is at http://www.drugscience.org/States/US/US_home.htm.

         With more than 29,000 members and 100,000 e-mail subscribers nationwide, the Marijuana Policy Project is the largest marijuana policy reform organization in the United States. MPP believes that the best way to minimize the harm associated with marijuana is to regulate marijuana in a manner similar to alcohol. For more information, please visit http://MarijuanaPolicy.org.

####

Maine Votes “Yes” on Medical Marijuana Dispensaries

FOR IMMEDIATE RELEASE                                                                                             
NOVEMBER 3, 2009

Maine Votes “Yes” on Medical Marijuana Dispensaries,

Becomes 3rd State to License Medical Marijuana Providers; Vote Seen as Latest Advance Spurred by Obama Policy

CONTACT: Bruce Mirken, MPP director of communications …………… 415-585-6404 or 202-215-4205

AUGUSTA, MAINE — In a landmark vote, Maine voters today approved Question 5, making the state the third in the country to license nonprofit organizations to provide medical marijuana to qualified patients and the first ever to do so by a vote of the people. With 49 percent of the vote tallied, the measure was cruising to an easy win with 60.2 percent voting “yes” and 39.8 percent voting “no.”

         Under the measure, the state will license nonprofit organizations to provide medical marijuana to qualified patients and set rules for their operation. While 13 states permit medical use of marijuana, only Rhode Island and New Mexico have similar dispensary provisions, both of which were adopted by the states’ legislatures. Maine’s original medical marijuana law was passed in 1999.

         “This is a dramatic step forward, the first time that any state’s voters have authorized the state government to license medical marijuana dispensaries,” said Rob Kampia, executive director of the Marijuana Policy Project in Washington, D.C., which drafted the initiative and provided start-up funding for the campaign. “Coming a decade after passage of Maine’s original marijuana law, this is a huge sign that voters are comfortable with these laws, and also a sign that the recent change of policy from the Obama administration is having a major impact.”  

         In October, the U.S. Department of Justice issued a formal policy indicating that federal prosecutors should not prosecute medical marijuana activities authorized by state law.

         Question 5 also expands the list of medical conditions qualifying for protection under Maine’s law to include several conditions that are included in most other medical marijuana states, including intractable pain, agitation of Alzheimer’s disease, and amyotrophic lateral sclerosis (“Lou Gehrig’s disease”).

         With more than 29,000 members and 100,000 e-mail subscribers nationwide, the Marijuana Policy Project is the largest marijuana policy reform organization in the United States. MPP believes that the best way to minimize the harm associated with marijuana is to regulate marijuana in a manner similar to alcohol. For more information, please visit http://MarijuanaPolicy.org.

####

Subscribe to Press Release